The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market By 2030 Based On Its 2026 Value?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market has witnessed swift growth recently. It is projected to increase from $39.69 billion in 2025 to $45.88 billion in 2026, at a compound annual growth rate (CAGR) of 15.6%. The expansion observed in the past can be attributed to breakthroughs in COVID-19 vaccines, preceding viral vector research, global pandemic readiness programs, developments in genomic sequencing, and early trials of nucleic acid vaccines.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is anticipated to undergo rapid expansion in the coming years. It is projected to reach $82.61 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.8%. This anticipated growth can be attributed to factors such as the rise of personalized cancer vaccines, the expansion of infectious disease pipelines, quicker platform-based approvals, increased funding in biotechnology, and broader use of therapeutic vaccines. Key trends during the forecast period are expected to include self-amplifying mRNA platforms, optimized lipid nanoparticle delivery, modular vaccine platform designs, rapid adaptation to pathogen targets, and advanced adjuvant systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp

Which Growth Factors Are Strengthening The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Landscape?

The rising need for personalized medicine is anticipated to fuel the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market moving ahead. This medical strategy involves customizing disease prevention and treatment approaches according to an individual’s genetic makeup, molecular traits, and unique health circumstances. The surge in personalized medicine demand stems from the increasing occurrence of complex and persistent illnesses, which necessitate precise and patient-focused therapeutic interventions to enhance treatment effectiveness and safety results. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for swift, adaptable, and highly targeted vaccine and treatment designs, which can be adapted to specific genetic and disease profiles, thereby supporting precision healthcare. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and healthcare body, showed that in 2023, the FDA sanctioned 16 novel personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is propelling the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

What Segment Types Are Included In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Analysis?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

Which Trends Are Contributing To Changes In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Leading enterprises within the mRNA and next-generation vaccine platforms market are concentrating on creating advanced mRNA-based COVID-19 vaccines, with the goal of strengthening immune persistence, expanding protection against variants, and elevating overall vaccine efficacy. These advanced mRNA vaccines utilize enhanced mRNA engineering and delivery methods, offering more extensive and lasting protection against current and developing SARS-CoV-2 variants. They also boost safety, stability, and ease of storage, alongside enabling swift adjustments to evolving viruses. An illustration of this is Moderna Inc., a US-based biotechnology company, launching mNEXSPIKE in June 2025. This next-generation COVID-19 vaccine is engineered to bolster defenses against both prevalent and newly appearing SARS-CoV-2 variants, featuring an updated spike protein antigen that more accurately aligns with recent variants. Its objective is to provide superior immune durability and efficacy, thereby assisting current COVID-19 prevention initiatives and future booster approaches.

Who Are The Businesses Driving Activity In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Access The Complete Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report

Which Region Is The Dominant Market In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model